<DOC>
	<DOCNO>NCT00455221</DOCNO>
	<brief_summary>The primary purpose study evaluate safety peptide-gene vaccine CML patient Imatinib treatment . We also perform laboratory test suggest biological response .</brief_summary>
	<brief_title>Safety Assessment Multipeptide-gene Vaccine CML</brief_title>
	<detailed_description>- Patients continue take current dose Imatinib . - Patients undergo HLA-typing define HLA A , B , DR. - One constant dose ten bcr-abl peptide ( 100μg ) administer subcutaneously patient triweekly 8 dos . - Four different dos IL-12 GM-CSF plasmid test trial . The plasmid administer subcutaneously near vaccination site 24 hour vaccination . - The first three patient receive low dose IL-12 GM-CSF plasmid . If well tolerate , next three patient receive low dose IL-12 plasmid high dose GM-CSF plasmid . If well tolerate , next three patient receive high dose IL-12 low dose GM-CSF plasmid . If well tolerate , next three patient receive high dose IL-12 GM-CSF plasmid . Once assign dose , patient receive dose throughout participation trial . - Each vaccination may consist one several shot place skin forearm , thigh trunk area , sit rotate per vaccination . - During clinic visit vaccination , blood test draw . If , course therapy , side effect develop doctor feel pose threat patient , treatment stop . - Patients also undergo DTH skin test vaccination see immune reaction occur injection site . - Patients ' lymphocyte test vaccination regard IFN-γ IL-4 production ass immune system activation . - During course treatment measure effect vaccine patient CML every three month : 1. bone marrow biopsy aspirate analysis , 2. measure amount BCR-ABL detectable RT-PCR patient ' peripheral blood bone marrow aspirate .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients Philadelphia chromosome positive CML : 1. subtype b3a2 2 . In first complete hematologic response ; 3. receive imatinib &gt; 12 month last 3 month stable dose least 400 mg/day ; 4. PCR detectable BCRABL transcript qRTPCR , 5. persistent disease , define &lt; 1 log reduction peripheral blood bone marrow BCRABL transcript level compare standardized baseline . Greater equal 18 year age No know infection human immunodeficiency virus Physician patient willingness maintain baseline dose imatinib throughout study period Written inform consent obtain patient Female patient pregnant breast feed adult childbearing age use adequate birth control . Current use systemic immunosuppressive medication ALT AST &gt; 3X Upper limit Normal Prior allogeneic stem cell transplantation Other experimental therapy within past two month Prior participation vaccine study within past six month Oxygen saturation le 95 % room air History recent acute myocardial infarction , unstable angina , pulmonary decompensation require hospitalization within past 3 month . Concurrent uncontrolled psychiatric medical condition may interfere study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>CML</keyword>
	<keyword>Imatinib</keyword>
	<keyword>vaccine</keyword>
	<keyword>peptide</keyword>
	<keyword>gene</keyword>
	<keyword>MRD</keyword>
	<keyword>DNA</keyword>
</DOC>